Lonza Stock - analyst consensus and long-term positioning

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 15:58 CET. Details in the imprint.

Lonza (CH0013841017) remains a core European name in contract drug manufacturing, even without fresh market-moving headlines today. Analyst data providers still show a mixed but broadly constructive consensus on earnings growth and margins for the next few years.

How analysts view Lonza

Without a fresh ad-hoc release, the reference point for Lonza stock is the latest reported full-year 2024 results and guidance update from January 2025, where management outlined mid- to high-single-digit sales growth and margin improvement targets over the medium term according to the company’s publications.

Data from consensus aggregators indicates that most covering banks still rate Lonza between Hold and Buy, with an average 12-month target price that implies mid-teens percentage upside from recent trading levels.

Long-term business model in focus

For a Saturday view, the focus shifts to Lonza’s long-term positioning as a contract development and manufacturing organization specializing in biologics, small molecules and cell-and-gene-therapy platforms. The company emphasizes high-barrier, multi-year supply agreements with global pharma and biotech clients in its strategy materials.

This model relies on sticky customer relationships and significant upfront capital expenditure, but it provides recurring manufacturing revenues once new capacity is filled, a dynamic that analysts frequently highlight when discussing the stock’s valuation.

How the company makes money

Lonza generates most of its revenue by producing active pharmaceutical ingredients and finished drug products for third parties, with a particular emphasis on biologics manufacturing, including monoclonal antibodies and other complex modalities used in oncology and immunology.

Where the stock trades today

The shares of Lonza (CH0013841017) trade on SIX Swiss Exchange at CHF 000.00 as of 06/20/2026, 15:58 CET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.